Alexandr L. Gintsburg

Alexandr L. Gintsburg

Auto-generated profile, based on publicly available information

Alexandr L. Gintsburg

Department of Genetics and Molecular Biology of Bacteria, Federal State Budget Institution «National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N.F. Gamaleya» of the Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Molecular Genetics, Microbiology and Virology
Verified
Journal Article
Closed access
PDF file
ITI. G. Tiganova
I. G. Tiganova
YZYu. S. Zhizhimova
Yu. S. Zhizhimova
NPN. I. Philipova
N. I. Philipova
ETEteri Tolordava
Eteri Tolordava
NAN. V. Alekseeva
N. V. Alekseeva
AGA. L. Gintsburg
A. L. Gintsburg
Antibacterial photodynamic therapy (APDT) is a promising method of treatment of local infections, based on photochemical reaction of photosensitizer (PS) u

14 March 2020 in Epidemiology and Vaccinal Prevention
Verified
Journal Article
Open access
PDF file
LALusine Avetisyan
Lusine Avetisyan
ISI. A. Shaginyan
I. A. Shaginyan
MCMarina Chernukha
Marina Chernukha
EBE. M. Burmistrov
E. M. Burmistrov
OMO. S. Medvedeva
O. S. Medvedeva
AGA. L. Ginzburg
A. L. Ginzburg
Эпидемиологический надзор за хроническими инфекциями легких, вызванными бактериями Burkholderia cepacia complex , бактериями рода Achromobacter, Pseudomonas аeruginosa и метициллинрезистентным Staphylococcus aureus , у больных муковисцидозом

22 April 2019 in Siberian Medical Review
Verified
Journal Article
Closed access
NRNatalia Ryzhova
Natalia Ryzhova
NMN. F. Gamaleya National Research Center for Epidemiology and Microbiology
N. F. Gamaleya National Research Center for Epidemiology and Microbiology
OVOlga L. Voronina
Olga L. Voronina
ELE.V. Loseva
E.V. Loseva
EAEkaterina Aksenova
Ekaterina Aksenova
RGResearch Centre for Medical Genetics
Research Centre for Medical Genetics

24 November 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
IFIrina Favorskaya
Irina Favorskaya
DSDmitry Shcheblyakov
Dmitry Shcheblyakov
IEIlias B Esmagambetov
Ilias B Esmagambetov
ISInna Shuliakova
Inna Shuliakova
IAIrina A. Alekseeva
Irina A. Alekseeva
AGAlexandr L. Gintsburg
Alexandr L. Gintsburg
Virus-neutralizing antibodies are one of the few treatment options for COVID-19. The evolution of SARS-CoV-2 virus has led to the emergence of virus variants with reduced sensitivity to some antibody-based therapies. The development of potent antibodies with a broad spectrum of neutralizing activity is urgently needed. Here we isolated a panel of single-domain antibodies that specifically bind to the receptor-binding domain of SARS-CoV-2 S glycoprotein. Three of the selected antibodies exhibiting most robust neutralization potency were used to generate dimeric molecules. We observed that these modifications resulted in up to a 200-fold increase in neutralizing activity. The most potent heterodimeric molecule efficiently neutralized each of SARS-CoV-2 variant of concern, including Alpha, Beta, Gamma, Delta and Omicron variants. This heterodimeric molecule could be a promising drug candidate for a treatment for COVID-19 caused by virus variants of concern.